[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561408":3},{"organization":4,"outcomesModule":7,"designInfo":36,"detailedDescription":11,"studyPopulation":11,"armGroups":42,"interventions":50,"overallOfficials":11,"centralContacts":64,"locations":73,"responsibleParty":91,"collaborators":11,"id":93,"slug":11,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":11,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":11,"studyType":105,"phases":106,"briefSummary":109,"conditions":110,"keywords":11,"overallStatus":76,"whyStopped":11,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Shanghai Hengrui Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":11},[9,13,17],{"measure":10,"description":11,"timeFrame":12},"Determination of Recommended Phase II dose (RP2D)",null,"From first dose of study treatment until the end of Cycle 1（up to 21 days）",{"measure":14,"description":15,"timeFrame":16},"Objective Response Rate (ORR)","The percentage of participants with a confirmed CR or PR according to RECIST v1.1 criteria.","From time of first dose of SHR-A2102 or Adebrelimab or SHR-8068 until the date of objective disease progression or death (up to 12 months)",{"measure":18,"description":11,"timeFrame":19},"Incidence and severity of AEs","The observation period ended at the end of the 21-day period after the first dose of SHR-A2102 or Adebrelimab or SHR-8068 (up to 21 days)",[21,24,28,32],{"measure":22,"description":23,"timeFrame":16},"Disease Control Rate (DCR)","The percentage of participants who have a best objective response of confirmed CR or PR or who have SD after start of treatment.",{"measure":25,"description":26,"timeFrame":27},"Duration of Response (DoR)","The time from the date of first response until date of disease progression or death in the absence of disease progression.","From time of first dose of objective disease progression until the date of objective disease progression or death (up to 12 months)]",{"measure":29,"description":30,"timeFrame":31},"Progression free Survival (PFS)","Progression-free survival is defined as the time from the start of treatment until the date of objective disease progression or death.","From time of first dose of objective disease progression until the date of objective disease progression or death (up to 12 months)",{"measure":33,"description":34,"timeFrame":35},"Overall Survival (OS)","The time until death due to any cause.","From time of first dose of objective disease progression until the date of death (up to 24 months)",{"allocation":37,"interventionModel":38,"interventionModelDescription":11,"primaryPurpose":39,"observationalModel":11,"timePerspective":11,"maskingInfo":40},"NA","SINGLE_GROUP","TREATMENT",{"masking":41,"maskingDescription":11,"whoMasked":11},"NONE",[43],{"label":44,"type":45,"description":11,"interventionNames":46},"SHR-A2102 in Combination with Adebrelimab and SHR-8068","EXPERIMENTAL",[47,48,49],"Drug: SHR-A2102","Drug: Adebelimab (SHR-1316)","Drug: SHR-8068",[51,56,60],{"type":52,"name":53,"description":54,"armGroupLabels":55,"otherNames":11},"DRUG","SHR-A2102","SHR-A2102: injection, 80mg\u002F bottle, intravenous drip",[44],{"type":52,"name":57,"description":58,"armGroupLabels":59,"otherNames":11},"Adebelimab (SHR-1316)","Adebelimab (SHR-1316): injection, 600mg(12mL)\u002F bottle, intravenous drip",[44],{"type":52,"name":61,"description":62,"armGroupLabels":63,"otherNames":11},"SHR-8068","SHR-8068: injection, 50mg（10mL）\u002F bottle, intravenous drip",[44],[65,70],{"name":66,"role":67,"phone":68,"phoneExt":11,"email":69},"Xin Xu","CONTACT","0518-82342973","xin.xu@hengrui.com",{"name":71,"role":67,"phone":68,"phoneExt":11,"email":72},"Yunfei Zhang","yunfei.zhang.yz277@hengrui.com",[74],{"facility":75,"status":76,"city":77,"state":78,"zip":79,"country":80,"countryCode":81,"cosmosGeoPoint":82,"geoPoint":87,"contacts":88},"Shanghai Chest Hospital","RECRUITING","Shanghai","Shanghai Municipality","200030","China","CN",{"type":83,"coordinates":84},"Point",[85,86],121.45806,31.22222,{"lat":86,"lon":85},[89],{"name":90,"role":67,"phone":11,"phoneExt":11,"email":11},"Hua Zhong",{"type":92,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100561408",false,"NCT06589778","A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","Safety, Tolerability, and Efficacy of SHR-A2102 in Combination With Adebrelimab, With SHR-8068, in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase IB\u002FII Open-Label, Multicenter Clinical Study","Inclusion Criteria:\n\n1. Subjects are able to give voluntary informed consent, understand the study and are willing to follow and complete all the test procedures.\n2. Age 18\\~70 years old.\n3. Pathologically confirmed unresectable locally advanced\u002Fmetastatic non-small cell lung cancer.\n4. At least one measurable lesion per RECIST v1.1 criteria.\n5. ECOG PS score: 0-1.\n\nExclusion Criteria:\n\n1. Active or symptomatic brain metastases.\n2. Previous diagnosis of any other malignancy.\n3. Clinically symptomatic moderate to severe ascites; Uncontrollable or moderate or above pleural effusion, pericardial effusion.\n4. Received anti-tumor therapy 4 weeks prior to initiation of study treatment.\n5. Uncontrolled tumor-related pain.\n6. Subjects with severe cardiovascular and cerebrovascular diseases.","ALL","18 Years","70 Years",{"count":103,"type":104},124,"ESTIMATED","INTERVENTIONAL",[107,108],"PHASE1","PHASE2","This study is a multicenter, open-label, dose-finding\u002Fefficacy-expanding Phase IB\u002FII clinical trial to evaluate SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer. The study consists of two phases: Phase IB to explore the safety\u002Ftolerability of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer; Phase II: To explore the efficacy of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer.",[111],"Non-Small Cell Lung Cancer","2024-11-07",{"date":114,"type":115},"2024-11-12","ACTUAL",{"date":117,"type":115},"2024-09-27",{"date":119,"type":104},"2026-04-30",{"name":5,"class":6},1]